News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary https://ir.immunitybio.com/news-releases/news-release-details/unmatched-long-term-bladder-preservation-36-months-over-80?field_nir_news_date_value[min]=

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-showcase-advances-bladder-and-prostate-cancer?field_nir_news_date_value[min]=

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-fda-submissions-supplemental-bla-nmibc?field_nir_news_date_value[min]=

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-execution-75-million-equity-financing?field_nir_news_date_value[min]=

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-host-key-opinion-leader-and-investor-meeting-provide?field_nir_news_date_value[min]=

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-first-dosing-recombinant-bcg-rbcg-us-and?field_nir_news_date_value[min]=